Baron Funds, an investment management ... Like other CROs, ICON is facing headwinds due to tighter management of R&D spend by pharmaceuticals, less biotechnology funding availability, a greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback